HLB Pharmaceutical to invest 55 billion won in Hyangnam plant expansion to boost production capacity

HLB Pharmaceutical will invest 55 billion won to expand production capacity and upgrade aging equipment.

HLB Pharmaceutical disclosed that its board of directors met on the 1st and approved a 55 billion won investment in expanding its Hyangnam GMP plant at 35, Jeyakgongdan 2-gil, Hyangnam-eup, Hwaseong, Gyeonggi Province.

The investment will fund construction of a new plant in Hyangnam, mechanical and utility work, and the purchase and installation of production equipment. The amount excludes value-added tax.

The 55 billion won investment represents 43.95% of the company’s equity of 125.1 billion won, based on its consolidated financial statements at the end of 2025. The company is not classified as a large corporation.

The investment period runs from the date of the board resolution through Jan. 31, 2028. The company said the investment is intended to “expand production capacity, upgrade aging production equipment and secure a stable production base.”

Two outside directors attended the board meeting, one was absent, and the auditor attended.

The company added that the investment amount and period are based on plans as of the date of the board resolution and may change depending on construction progress and changes in the business environment. Authority to determine and execute the details was delegated to the CEO.